Upadacitinib (CAS 1310726-60-3): A Comprehensive Product Introduction

Upadacitinib, with the CAS number 1310726-60-3, is a remarkable compound that has gained significant attention in the pharmaceutical and biomedical fields. This article aims to provide a detailed introduction to Upadacitinib, including its properties, uses, applications in various sectors, and the methods of its preparation.

Properties of Upadacitinib

Upadacitinib is a small – molecule Janus kinase (JAK) inhibitor. Chemically, it has a well – defined structure that allows it to interact specifically with JAK enzymes. In terms of physical properties, it exists in a solid state under normal conditions. Its solubility in different solvents is an important characteristic. It shows a certain degree of solubility in organic solvents such as dimethyl sulfoxide (DMSO), which is commonly used in laboratory settings for in – vitro studies. The melting point and boiling point of Upadacitinib are carefully determined through precise analytical techniques, and these values play a crucial role in its purification and formulation processes.

From a chemical stability perspective, Upadacitinib is stable under specific storage conditions. However, it may be sensitive to factors such as light, heat, and moisture. Therefore, proper storage in a cool, dry, and dark place is recommended to maintain its chemical integrity. Its chemical formula and molecular weight are key parameters that help in understanding its reactivity and interactions with other substances. The molecular weight of Upadacitinib is accurately calculated based on its atomic composition, which is essential for dosage calculations in pharmaceutical applications.

Uses of Upadacitinib

Pharmaceutical Applications

One of the primary uses of Upadacitinib is in the treatment of various autoimmune diseases. It acts by inhibiting the activity of JAK enzymes, which are involved in the signaling pathways of cytokines. Cytokines play a central role in the immune response, and dysregulation of cytokine signaling is often associated with autoimmune disorders. By blocking JAK enzymes, Upadacitinib can reduce the over – activation of the immune system, thereby alleviating the symptoms of these diseases.

For example, in the treatment of rheumatoid arthritis, Upadacitinib has shown promising results in clinical trials. Rheumatoid arthritis is a chronic inflammatory disorder that affects the joints, causing pain, swelling, and stiffness. Upadacitinib can target the underlying immune – mediated processes, leading to improved joint function and reduced disease activity. It has been approved for use in many countries as a treatment option for moderate – to – severe rheumatoid arthritis in patients who have an inadequate response or intolerance to conventional disease – modifying antirheumatic drugs (DMARDs).

Another significant application is in the treatment of psoriatic arthritis. Psoriatic arthritis is a type of arthritis that occurs in some people with psoriasis, a skin condition. Upadacitinib can not only improve the joint symptoms but also have a positive impact on the skin manifestations of psoriatic arthritis. It helps to reduce inflammation in both the joints and the skin, providing a comprehensive treatment approach for patients suffering from this complex disease.

Ulcerative colitis is also a target for Upadacitinib treatment. Ulcerative colitis is an inflammatory bowel disease that affects the large intestine and rectum. By modulating the immune response, Upadacitinib can reduce the inflammation in the intestinal mucosa, leading to remission of symptoms such as diarrhea, abdominal pain, and rectal bleeding. Clinical studies have demonstrated its efficacy in inducing and maintaining remission in patients with moderate – to – severe ulcerative colitis.

Applications in Other Fields

Research and Development

In the field of medical research, Upadacitinib serves as a valuable tool for studying the role of JAK enzymes in various biological processes. Scientists can use Upadacitinib to block JAK signaling in cell cultures and animal models to understand the downstream effects on cell growth, differentiation, and immune function. This research can provide insights into the pathogenesis of autoimmune diseases and potentially lead to the discovery of new therapeutic targets.

Moreover, Upadacitinib can be used in pre – clinical studies to evaluate the safety and efficacy of new drug candidates. By comparing the effects of different compounds with Upadacitinib, researchers can identify novel JAK inhibitors with improved properties, such as higher selectivity, lower toxicity, and better pharmacokinetic profiles.

Biotechnology

In the biotechnology industry, Upadacitinib can be used in the development of new biologic drugs. For example, it can be incorporated into the design of targeted drug delivery systems. By conjugating Upadacitinib with specific carriers, such as nanoparticles or liposomes, it can be delivered more precisely to the target cells or tissues, enhancing its therapeutic efficacy and reducing side effects. Additionally, Upadacitinib can be used in the production of monoclonal antibodies that target JAK – related pathways. These antibodies can be used for diagnostic and therapeutic purposes in the future.

Preparation Methods of Upadacitinib

The synthesis of Upadacitinib is a complex multi – step process that requires careful control of reaction conditions and purification steps. The starting materials for the synthesis are carefully selected based on their availability, reactivity, and cost – effectiveness. The first step usually involves the preparation of key intermediate compounds through various chemical reactions, such as condensation reactions, substitution reactions, and oxidation – reduction reactions.

For example, some of the intermediate compounds may be synthesized through the reaction of specific aromatic compounds with appropriate reagents to introduce functional groups. These functional groups are then further modified and combined in subsequent steps to form the core structure of Upadacitinib. The reaction conditions, including temperature, pressure, reaction time, and the choice of catalysts, are optimized to maximize the yield and purity of the intermediate products.

After the synthesis of the intermediate compounds, they are assembled to form the final Upadacitinib molecule. This step often involves a series of coupling reactions to connect the different parts of the molecule. Once the synthesis is complete, the crude product is purified through various techniques, such as chromatography, recrystallization, and distillation. Chromatography is commonly used to separate the desired product from impurities based on their different physical and chemical properties. Recrystallization can further improve the purity of the product by dissolving it in a suitable solvent and then allowing it to crystallize out under controlled conditions.

References

• Author1, Title1, Journal1, Volume1, Page1, Year1
• Author2, Title2, Journal2, Volume2, Page2, Year2
• Author3, Title3, Journal3, Volume3, Page3, Year3

Inquiry Form